Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Colorado
Clinical trial register · United States · industry-sponsored

Clinical Trials in Colorado, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Colorado

2073 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
California, Colorado, District of Columbia, Florida, Georgia, Indiana, Massachusetts, Missouri
2027-11-23
Not yet open
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
NCT07871877Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Clive Michelsen
Phase 1/2
60
Colorado
2027-07-01
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Arizona, Colorado, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2027-02-03
Recruiting
Amgen
Observational
60
Colorado
2027-01-15
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2027-01-11
By invitation
NS Pharma, Inc.
Phase 2
20
Colorado, Ohio, Virginia
2026-12-16
Not yet open
Boehringer Ingelheim
Phase 3
270
Arizona, California, Colorado, Illinois, Kansas, Maryland, Massachusetts, Michigan
2026-12-14
Not yet open
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Scancell Ltd
Phase 3
550
Colorado
2026-12-01
Not yet open
Eli Lilly and Company
Phase 2
120
California, Colorado, Georgia, Massachusetts, Ohio, Texas, Virginia
2026-12
Recruiting
Jade Biosciences, Inc.
Phase 3
480
Colorado, Florida, Georgia, Texas
2026-12
Not yet open
Bayer
Observational
2,400
Alabama, Arkansas, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
AstraZeneca
Phase 2
250
California, Colorado, Connecticut, Florida, Georgia, Illinois, South Carolina, Texas
2026-11-30
Not yet open
Boehringer Ingelheim
Phase 3
600
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Michigan
2026-11-25
Not yet open
Annovis Bio Inc.
Phase 2/3
400
Colorado, Florida, Georgia, New Jersey, North Carolina, Texas, Virginia
2026-11-21
Not yet open
Pediatric Adeno-Tonsillar Hypertrophy Treatment Post-Approval Study
NCT07931534Airway Obstruction Upper, Tonsillectomy, Adenoidectomy Surgery, Hypertrophy
ENTire Medical Ltd.
Not applicable
73
Colorado, Texas
2026-11-05
Recruiting
TG Therapeutics, Inc.
Phase 2
120
Colorado, Florida, Michigan, North Carolina, South Carolina
2026-11-01
Not yet open
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
NCT07883590Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Eli Lilly and Company
Phase 1
32
California, Colorado, District of Columbia, Illinois, Massachusetts
2026-11
Recruiting
Faron Pharmaceuticals Ltd
Phase 2
90
California, Colorado, Connecticut, Florida, Massachusetts, North Carolina, Tennessee, Texas
2026-11
Recruiting
Viatris Inc.
Phase 1/2
18
Arizona, California, Colorado, Florida, Kentucky, North Dakota, Oregon, Texas
2026-11
Recruiting
Kowa Research Institute, Inc.
Not applicable
340
California, Colorado, Georgia, Missouri, South Carolina, Texas, Virginia
2026-10-30
Not yet open
Smith & Nephew, Inc.
Not applicable
330
Colorado, Georgia, Indiana
2026-10-30
Recruiting
ALPFA Medical
Not applicable
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Nebraska
2026-10-28
Recruiting
Pfizer
Phase 3
656
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2026-10-26
Recruiting
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Recruiting
Vogenx, Inc.
Phase 2
36
California, Colorado, Florida, Georgia, North Carolina, Pennsylvania, Tennessee, Texas
2026-10-20
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Indiana
2026-10-16
Recruiting
Philips Clinical & Medical Affairs Global
Observational
85
Colorado
2026-10-15
Not yet open
Cerus Corporation
Phase 2
25
Colorado
2026-10-10
Recruiting
ModernaTX, Inc.
Phase 1
96
California, Colorado, Minnesota, Ohio, Texas, Virginia
2026-10-07
Recruiting
Bristol-Myers Squibb
Phase 1/2
84
California, Colorado, Florida, New York, Oregon, Pennsylvania, Texas
2026-10-06
Recruiting
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
Bristol-Myers Squibb
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-10-06
Recruiting
Medtronic MiniMed, Inc.
Not applicable
1,500
California, Colorado, Connecticut, Florida, Georgia, Idaho, Texas, Virginia
2026-10-05
Recruiting
TriGemX Bio, Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-10-02
Recruiting
Gilead Sciences
Phase 2
132
Colorado, Florida, Georgia, Tennessee
2026-10-01
Not yet open
Cochlear
Not applicable
200
Colorado
2026-10
Recruiting
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NCT07520006B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Nurix Therapeutics, Inc.
Phase 1/2
150
California, Colorado, Florida, Kansas, Nevada, New Jersey, Oregon, Pennsylvania
2026-09-30
Recruiting
Biomed Industries, Inc.
Phase 3
210
Arizona, California, Colorado, Florida, Illinois, Maryland, Massachusetts, New York
2026-09-30
Recruiting
vTv Therapeutics
Phase 2
40
California, Colorado, Georgia, North Carolina, Texas
2026-09-29
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois
2026-09-29
Recruiting
A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
NCT07725796Bladder (Urothelial, Transitional Cell) Cancer, NMIBC, Urothelial Carcinoma Bladder, Urothelial Carcinoma in Situ
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase 1
30
Arizona, California, Colorado, Florida, Massachusetts, Michigan, Nebraska, New York
2026-09-28
Recruiting
NervGen Pharma
Phase 3
150
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-09-28
Recruiting
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09-25
Recruiting
Phathom Pharmaceuticals, Inc.
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Idaho, Nevada, New York
2026-09-25
Recruiting
Transcend Therapeutics
Phase 3
300
Colorado, Florida, Georgia, New Jersey, Utah
2026-09-25
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Massachusetts
2026-09-24
Recruiting
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
Knee Cartilage Repair Registry
NCT07786207Knee Injuries, Joint Surface Knee Lesions
Smith & Nephew, Inc.
Observational
1,000
Colorado, District of Columbia, Illinois, Indiana, Kentucky, Minnesota, Oklahoma, Pennsylvania
2026-09-23
Recruiting
Vertanical GmbH
Phase 3
810
Alabama, Arizona, California, Colorado, Florida, Kansas, Massachusetts, North Carolina
2026-09-22
Recruiting
Adneuris Therapeutics, Inc.
Phase 3
160
Arizona, California, Colorado, Georgia, Illinois, Maryland, New Jersey, Oklahoma
2026-09-22
Recruiting
4D Molecular Therapeutics
Phase 3
514
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2026-09-18
Recruiting
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
By invitation
Vertex Pharmaceuticals Incorporated
Phase 3
605
Colorado, Florida, Idaho, Texas
2026-09-17
Recruiting
YolTech Therapeutics Co., Ltd
Phase 2
36
Alabama, Colorado, Missouri, Pennsylvania
2026-09-16
By invitation
Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage
NCT07218185Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Cerus Corporation
Observational
320
Colorado, Florida, Maryland, Missouri
2026-09-15
Recruiting
CSL Behring
Phase 3
63
California, Colorado, Florida, Indiana, Maryland, New Jersey, New York, North Carolina
2026-09-15
Recruiting
WATER IV PCa (AS Sub-study)
NCT07650448Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
333
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Maryland
2026-09-11
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
Device for Treating Generalized Anxiety
NCT07819773Generalized Anxiety Disorder (GAD)
BTL Industries Ltd.
Not applicable
40
Colorado, Illinois, Indiana
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Kansas
2026-09-08
Recruiting
Bristol-Myers Squibb
Phase 3
850
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Minnesota, Missouri
2026-09-08
Recruiting
GlaxoSmithKline
Phase 3
218
California, Colorado, Florida, Kansas, South Carolina, Texas
2026-09-03
Recruiting
Orphalan
Phase 3
38
Colorado, Connecticut, Michigan
2026-09-03
Recruiting
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Recruiting
Genentech, Inc.
Phase 4
100
Alabama, Arizona, Colorado, Florida, Georgia, Tennessee
2026-09-02
Not yet open
To Evaluate the Clinical Impact of the Point Powered System
NCT07135947Amputation; Traumatic, Hand
Point Designs
Not applicable
10
Colorado
2026-09-01
Recruiting
Bayer
Phase 2
360
California, Colorado, Massachusetts, Michigan, Minnesota, North Carolina, Texas
2026-09-01
Recruiting
Rapport Therapeutics Inc.
Phase 3
312
Alabama, Arkansas, Colorado, Florida, Hawaii, Illinois, Nebraska, New York
2026-09-01
Recruiting
MaioRegen Prime Study for the Treatment of Deep Osteochondral Lesion of the Knee
NCT07332182Osteochondral Lesions of the Knee Joint, Osteochondritis Dissecans (OCD), Early Osteoarthritis
Fin-Ceramica Faenza Spa
Not applicable
400
California, Colorado, Illinois, Michigan, Ohio, Oregon, Tennessee, Texas
2026-09
Recruiting
Vaginal Wall Retraction Using VuSleeve
NCT07846527Adult Females
Ceek Women's Health, INC
Observational
500
Colorado, Georgia
2026-09
Recruiting
Brexanolone Lifting Outcomes Of Moms
NCT07822321Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
Lipocine Inc.
Phase 3
120
Arizona, California, Colorado, Georgia, Idaho, Illinois, Louisiana, Nevada
2026-09
Recruiting
Novo Nordisk A/S
Phase 3
950
Alabama, California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana
2026-08-31
Recruiting
Pfizer
Phase 3
440
California, Colorado, District of Columbia, Georgia, Iowa, Louisiana, Maryland, Missouri
2026-08-31
Recruiting
PULmonary Stimulation for Asthma Relief
NCT07709754Moderate to Severe Asthma
Spiro Medical, Inc.
Not applicable
30
Colorado, Florida
2026-08-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
960
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Maryland
2026-08-27
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland
2026-08-27
Recruiting
MBX Biosciences
Phase 3
160
California, Colorado, Florida, Georgia, Louisiana, Mississippi, Nebraska, Nevada
2026-08-26
Recruiting
Biosense Webster, Inc.
Not applicable
1,070
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Kentucky
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
VarmX B.V.
Phase 3
800
Arizona, California, Colorado, Delaware, Florida, Iowa, Massachusetts, Michigan
2026-08-18
Recruiting
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
NCT07745361Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Monte Rosa Therapeutics, Inc
Phase 2
25
California, Colorado, Kansas, Maryland, Michigan, Nebraska, New Jersey, North Carolina
2026-08-18
Recruiting
KalVista Pharmaceuticals, Ltd.
Phase 4
100
Colorado
2026-08-17
Recruiting
Medtronic Cardiac Ablation Solutions
Not applicable
260
Colorado, Indiana, New York, North Carolina, Ohio, Texas
2026-08-17
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Longevity Metrics AI/ML Development Study
NCT07808619Aging, Mortality, Cardiovascular Disease Prevention, Metabolic Syndrome
Longevity Metrics, Inc.
Observational
1,000,000
Colorado
2026-08-08
Recruiting
Eli Lilly and Company
Phase 2
606
Alabama, California, Colorado, Florida, Illinois, Indiana, Massachusetts, Michigan
2026-08-07
Recruiting
Novartis Pharmaceuticals
Phase 2
164
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2026-08-04
Recruiting
Digestive Care, Inc.
Observational
30
Colorado, District of Columbia, New York, Ohio, Oregon, Tennessee, Texas, Washington
2026-08-03
Recruiting
TriGemX Bio, Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Not yet open
Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
NCT07675876Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Carcinex Inc
Phase 1
10
Colorado
2026-08
Recruiting
VectivBio AG
Phase 3
124
California, Colorado, District of Columbia, Florida, Illinois, Kentucky, Michigan, New York
2026-08
Recruiting
AbbVie
Phase 2
2,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-07-31
Recruiting
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Altimmune, Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2026-07-30
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2026-07-29
Recruiting
Boehringer Ingelheim
Phase 3
448
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Illinois, Louisiana
2026-07-27
Recruiting
AstraZeneca
Phase 1/2
101
California, Colorado, Florida, Georgia, Missouri, New Jersey, Ohio, Tennessee
2026-07-27
Recruiting
Bristol-Myers Squibb
Phase 2
254
California, Colorado, Georgia, Maryland, Massachusetts, Michigan, Minnesota, New York
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
AstraZeneca
Phase 3
230
Colorado, Maryland, Michigan, New Jersey, New York, North Carolina, Ohio, Utah
2026-07-24
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
Verastem, Inc.
Phase 2
105
Arizona, California, Colorado, Florida, Georgia, Illinois, New Jersey, New York
2026-07-22
Recruiting
Boehringer Ingelheim
Phase 3
35
California, Colorado, Maryland, Massachusetts, Minnesota, Ohio, Pennsylvania
2026-07-21
Recruiting
CardiacSense Ltd.
Not applicable
100
Colorado
2026-07-21
Recruiting
DBC-664 in Adult Patients With Solid Tumors
NCT07705035Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
Duboce Biopharmaceuticals, Inc.
Phase 1
210
Colorado, Michigan, Missouri, New Jersey, New York, Tennessee, Texas
2026-07-17
Recruiting
MoblO2 to Maintain Oxygenation
NCT07704567COPD (Chronic Obstructive Pulmonary Disease), Intersitital Lung Disease
Minnesota HealthSolutions
Not applicable
48
Colorado
2026-07-09
Recruiting
Jazz Pharmaceuticals
Phase 3
120
Alabama, California, Colorado, Delaware, Florida, Georgia, Maryland, Michigan
2026-07-09
Recruiting
AstraZeneca
Phase 3
600
Arkansas, California, Colorado, Florida, Georgia, Maryland, New York, North Carolina
2026-07-08
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
134
California, Colorado, Florida, Iowa, Massachusetts, Michigan, Missouri, New Jersey
2026-07-06
Recruiting
Sanofi
Phase 1/2
140
Colorado, Florida, Pennsylvania, Texas
2026-07-02
Recruiting
TriGemX Bio, Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Ohio, Tennessee
2026-07-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2026-07-01
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Not yet open
Shockwave Medical, Inc.
Not applicable
185
Arizona, Colorado, Florida, Georgia, Louisiana, Missouri, New York, North Carolina
2026-07
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
California, Colorado, Minnesota, New Jersey, Pennsylvania, Texas
2026-06-30
Recruiting
Neuvosyn Laboratories, LLC
Phase 3
466
California, Colorado, Florida, Idaho, Massachusetts, Nevada, North Carolina, South Carolina
2026-06-30
Recruiting
Happitech BV
Observational
554
Arkansas, Colorado, Louisiana, Oklahoma
2026-06-30
Recruiting
Expedition Therapeutics, Inc
Phase 2
600
Arizona, California, Colorado, Florida, Georgia, Indiana, Kansas, Louisiana
2026-06-30
Recruiting
Janssen Research & Development, LLC
Phase 2
230
Arizona, California, Colorado, Missouri, Ohio, Tennessee, Utah
2026-06-30
Recruiting
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
Study of NTB-928 in R/R OC
NCT07690189Relapsed/Refractory Ovarian Carcinoma
TeneoSeven, Inc.
Phase 1
90
Alabama, California, Colorado, Nebraska, New York
2026-06-29
Recruiting
Trevi Therapeutics
Phase 3
306
California, Colorado, Florida, Georgia, Kentucky, Louisiana, Minnesota, Missouri
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
NCT07749170Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Penumbra Inc.
Observational
250
Colorado, Connecticut, Kentucky, New York, North Carolina, Pennsylvania, South Carolina, Tennessee
2026-06-26
Recruiting
GlaxoSmithKline
Phase 3
34
Alabama, Colorado, South Dakota
2026-06-25
Recruiting
OHB Pediatrics Ltd.
Phase 3
165
California, Colorado, Florida, Illinois, North Carolina, Tennessee
2026-06-23
Recruiting
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency
Kardigan, Inc.
Phase 2
140
Colorado, Florida, Illinois, Michigan, New York, Ohio, South Carolina, Tennessee
2026-06-23
By invitation
Transcend Therapeutics
Phase 3
300
Arkansas, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Ohio
2026-06-22
Active, closed
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Recruiting
Pfizer
Phase 3
1,200
Alabama, California, Colorado, Florida, Idaho, Kentucky, Louisiana, Massachusetts
2026-06-15
Recruiting
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
Janssen Research & Development, LLC
Observational
150
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Indiana
2026-06-12
Active, closed
AstraZeneca
Phase 2
326
California, Colorado, District of Columbia, Florida, Illinois, Massachusetts, Missouri, New York
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
California, Colorado, Florida, Georgia, Maryland, Michigan, Missouri, New Jersey
2026-06-11
Recruiting
Health Ahead Comparative Effectiveness Study
NCT07669168Health Services Accessibility, Rural Health, Medically Underserved Area, Preventive Health Services
William Brandenburg, MD
Not applicable
1,000,000
Colorado
2026-06-09
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Quetzal Therapeutics
Phase 3
150
Alabama, California, Colorado, Georgia, Kentucky, Maryland, Michigan, New York
2026-06-08
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
570
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
ML Bio Solutions, Inc.
Phase 3
107
Arkansas, California, Colorado, Florida, Iowa, Kansas, Maryland, Minnesota
2026-06-05
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Kentucky, Louisiana, Minnesota, Texas
2026-06-03
Recruiting
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
NCT07290140Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Airiver Medical, Inc.
Not applicable
300
Alabama, California, Colorado, Iowa, Kansas, Kentucky, New York, Pennsylvania
2026-06-01
Not yet open
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
NCT04457076Contraception, Women at Risk for Pregnancy
Sebela Women's Health Inc.
Phase 3
1,525
California, Colorado, Georgia, Hawaii, Indiana, Minnesota, Missouri, Nevada
2026-06-01
Recruiting
Allterum Therapeutics, Inc
Phase 1
24
Colorado, Illinois, Indiana, New York, Ohio, Pennsylvania, Texas
2026-06-01
Recruiting
Bayer
Phase 3
117
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2026-06-01
Active, closed
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Recruiting
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Not yet open
A Study of CS231295 in Patients With Advanced Solid Tumors
NCT07612488Advance Solid Tumors, Advanced Malignant Solid Tumors
ThalassaX Therapeutics United States Ltd
Phase 1
42
Colorado, Florida, Massachusetts, Tennessee
2026-06
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
BioMarin Pharmaceutical
Phase 4
12
California, Colorado, Florida, Illinois, Indiana, Minnesota, New York, Oregon
2026-05-29
Recruiting
Centessa Pharmaceuticals (UK) Limited
Phase 2/3
222
Alabama, Colorado, Florida, Georgia, Michigan, Mississippi, North Carolina, Ohio
2026-05-29
Recruiting
Pfizer
Phase 3
3,230
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-05-29
Recruiting
Vericel Corporation
Phase 3
309
Arizona, California, Colorado, District of Columbia, Kansas, Minnesota, North Carolina, Pennsylvania
2026-05-28
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-05-27
Recruiting
The Impact of Enhanced Music & Natural Visuals on Emotional Health
NCT07676110Emotion Management Skills, Lifestyle, Healthy, Lifestyle Intervention, Recovery
soundBrilliance LLC
Not applicable
200
Colorado, Nebraska, Nevada
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-23
Active, closed
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Arizona, California, Colorado, Florida, Georgia, Kentucky, Louisiana, Missouri
2026-05-22
Recruiting
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Lumos Pharma
Phase 3
150
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Indiana, Iowa
2026-05-20
Recruiting
Jade Biosciences, Inc.
Phase 2
30
California, Colorado, Florida, Texas
2026-05-19
Recruiting
AbbVie
Phase 1/2
210
California, Colorado, Florida, Massachusetts, Tennessee, Texas
2026-05-15
Recruiting
Hoffmann-La Roche
Phase 3
138
Colorado, Iowa
2026-05-15
Recruiting
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
NCT07392892Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Pfizer
Phase 2/3
840
California, Colorado, Florida, Illinois, Kansas, Maryland, Missouri, Nevada
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-05-13
Recruiting
Sanofi
Phase 3
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Minnesota
2026-05-12
Recruiting
A Study to Assess the Safety, Tolerability and Efficacy of ION775
NCT07604974Hypertriglyceridemia, Severe Hypertriglyceridemia
Ionis Pharmaceuticals, Inc.
Phase 2
72
California, Colorado, Florida, Georgia, Indiana, Kentucky, Michigan, Ohio
2026-05-12
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
390
Arkansas, California, Colorado, Delaware, Illinois, Indiana, Michigan, Missouri
2026-05-11
Recruiting
Genmab
Phase 2
160
California, Colorado, Florida, Michigan, Tennessee, Texas
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Definium Therapeutics US, Inc.
Phase 3
165
Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri
2026-05-10
Recruiting
Crystalys Therapeutics
Phase 2
90
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2026-05-08
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Ascendis Pharma Bone Diseases A/S
Phase 3
36
Colorado, Illinois, Minnesota, Nevada, New Jersey, New York, North Carolina, Texas
2026-05-07
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Colorado, Massachusetts, Nebraska, Ohio
2026-05-06
Recruiting
Tulavi Therapeutics,Inc.
Observational
1,000
California, Colorado, Florida, Texas
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
California, Colorado, Florida, Illinois, Michigan, Minnesota, Missouri, New York
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Florida, Illinois, Michigan, Missouri, Montana
2026-05-04
Recruiting
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Maine
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC
Phase 1/2
280
California, Colorado, Ohio, Tennessee
2026-05-03
Not yet open
Occlutech AFR Fontan Study
NCT07532369Failure of Fontan Type Circulation, Fenestration, Univentricular Heart, Congenital Anomaly
Occlutech International AB
Observational
25
Alabama, California, Colorado, Illinois, North Carolina, Texas
2026-05-01
Recruiting
Insulet Corporation
Not applicable
350
California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana, Massachusetts
2026-04-30
Recruiting
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
NCT07469891Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis
Prelude Therapeutics Incorporated
Phase 1
100
California, Colorado, Florida, Michigan, Pennsylvania, Tennessee, Texas
2026-04-29
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Hoffmann-La Roche
Phase 3
360
California, Colorado, Florida, Indiana, Iowa, Michigan, Minnesota, Texas
2026-04-27
Recruiting
Human Observatory Study
NCT07646782Aging, Mortality, All-cause Mortality, Life Expectancy
Longevity Metrics, Inc.
Observational
1,000,000
Colorado
2026-04-25
Recruiting
Phase 2 Study to Assess the Safety and Efficacy of ANG003
NCT07450547Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Anagram Therapeutics, Inc.
Phase 2
113
California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas, Kentucky
2026-04-24
Recruiting
Op-T LLC
Phase 2
72
Alabama, California, Colorado, Illinois, Washington
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
California, Colorado, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Michigan
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2026-04-23
Recruiting
Aurinia Pharmaceuticals Inc.
Phase 4
150
California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri, Nevada
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
BioNTech SE
Phase 3
736
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, New York
2026-04-22
Recruiting
Faeth Therapeutics
Phase 1/2
32
California, Colorado, Florida, Oregon, Tennessee, Texas
2026-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 2
405
California, Colorado, Florida, Michigan, Mississippi, Montana, North Carolina, Ohio
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Active, closed
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
Blueprint Medicines Corporation
Observational
150
Colorado, Illinois, Maryland, Massachusetts, Michigan, Missouri, Utah
2026-04-15
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
Hoffmann-La Roche
Phase 3
100
Colorado, Connecticut, Florida, Georgia, Missouri, New York, Ohio, Pennsylvania
2026-04-15
Recruiting
Aktiia SA
Not applicable
200
Colorado
2026-04-14
Recruiting
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Recruiting
Bayer
Phase 1
130
Arizona, California, Colorado, New York, Texas
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
California, Colorado, Georgia, Iowa, Minnesota, New Jersey, New York, North Carolina
2026-04-07
Recruiting
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Active, closed
Cochlear
Not applicable
56
Colorado, Florida, Iowa, Michigan, Minnesota, Missouri, New York, Ohio
2026-04-03
Recruiting
Transcend Therapeutics
Phase 3
300
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Louisiana
2026-04-02
Recruiting
Vergent Bioscience, Inc.
Phase 3
132
California, Colorado, Florida, Michigan, Minnesota, Pennsylvania, Texas
2026-03-31
By invitation
Okami Medical ALPHA Registry
NCT07525518Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
Okami Medical, Inc.
Observational
500
California, Colorado, Florida, Massachusetts, North Carolina
2026-03-31
Recruiting
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
NCT07385313Soft Tissue Defects, Soft Tissue Wounds, Traumatic Soft Tissue Defect
Aroa Biosurgery Limited
Phase 4
30
Colorado, Texas
2026-03-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1
40
Alabama, California, Colorado, Florida, Georgia, Illinois, Michigan, Minnesota
2026-03-30
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
California, Colorado, Illinois, Minnesota, New York, North Carolina, Pennsylvania, Texas
2026-03-30
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals
Phase 2
32
California, Colorado, Georgia, Iowa, Minnesota
2026-03-26
By invitation
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
NCT07459660Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics
Phase 2
210
California, Colorado, Florida, Georgia, Ohio
2026-03-25
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
California, Colorado, Florida, Georgia, Kansas, Louisiana, Missouri
2026-03-24
Recruiting
Boehringer Ingelheim
Phase 2
132
Alabama, California, Colorado, Florida, Illinois, Maryland, Michigan, New York
2026-03-23
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
By invitation
Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate (MF)
NCT07286201Chronic Rhinosinusitis (CRS), Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Polyganics BV
Not applicable
110
Colorado, Georgia, Illinois, Louisiana, Maryland, South Carolina, Texas, Utah
2026-03-19
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2026-03-17
Recruiting
Gilead Sciences
Observational
3,000
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2026-03-17
Recruiting
BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System
NCT07118358Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Biotronik, Inc.
Not applicable
325
California, Colorado, Florida, Kentucky, Massachusetts, Michigan, Minnesota, Missouri
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Alabama, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Kentucky
2026-03-16
Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
NCT07143019Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
phenox Inc.
Not applicable
214
Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Massachusetts
2026-03-16
Recruiting
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
248
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-16
Recruiting
GlaxoSmithKline
Phase 3
456
Arkansas, California, Colorado, Florida, Louisiana, Oklahoma, Pennsylvania, South Dakota
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-03-12
Recruiting
Hoffmann-La Roche
Phase 2
100
California, Colorado, Iowa, New York, Rhode Island, South Carolina
2026-03-11
Recruiting
Medipost, Inc.
Phase 3
300
Alabama, Arizona, California, Colorado, Florida, Illinois, Kentucky, Louisiana
2026-03-11
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC
NCT07491497ALK-positive NSCLC, ALK-Positive Lung Cancer, ALK-positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc.
Phase 1/2
160
California, Colorado, Massachusetts, Missouri, New York, North Carolina, Ohio, Pennsylvania
2026-03-11
Recruiting
Takeda
Phase 3
1,182
Arizona, California, Colorado, Florida, Maryland, Michigan, North Carolina, Ohio
2026-03-11
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1/2
180
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
NCT06669403Sepsis, Community Acquired Pneumonia (CAP)
DrugOPT101
Op-T LLC
Phase 1
26
Colorado, New York
2026-03-09
Recruiting
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
Janssen Research & Development, LLC
Phase 3
600
California, Colorado, Florida, Georgia, Illinois, Louisiana, Michigan, New Jersey
2026-03-05
Recruiting
TOUCH® CMC 1 New Enrollment US Study
NCT07405983Osteoarthritis Thumb, Thumb Carpometacarpal Joint Osteoarthritis
Keri Medical SA
Observational
163
Colorado, Indiana, North Carolina, Texas
2026-03-04
Recruiting
AbbVie
Phase 1
127
California, Colorado, Florida, Georgia, Illinois, Michigan
2026-02-27
Recruiting
Boehringer Ingelheim
Phase 2
30
Arizona, California, Colorado, Florida, Georgia, Iowa, Kansas, Maryland
2026-02-27
Recruiting
Vor Biopharma
Phase 3
250
Arizona, California, Colorado, Florida, Idaho, Illinois, Louisiana, Maryland
2026-02-26
By invitation
Persona SoluTion PPS Femur PMCF
NCT07286513Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis
Zimmer Biomet
Observational
200
Colorado, Kentucky, Maryland, Ohio
2026-02-26
Recruiting
Appello Pharmaceuticals, Inc.
Phase 2
150
Arkansas, California, Colorado, Florida, Georgia, Indiana, Kansas, Kentucky
2026-02-25
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
California, Colorado, Connecticut, Florida, Michigan, New Jersey, New York, Tennessee
2026-02-24
Active, closed
Pfizer
Phase 3
1,078
California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska, New Jersey
2026-02-24
Recruiting
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
NCT07280065PTSD - Post Traumatic Stress Disorder
Senseye, Inc.
Phase 3
1,900
Colorado, Georgia, Idaho, Massachusetts, South Carolina
2026-02-23
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Active, closed
AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction
NCT07368959Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Aurion Biotech
Phase 3
130
Arizona, Arkansas, Colorado, Georgia, Missouri, North Carolina, Pennsylvania, South Carolina
2026-02-19
Recruiting
Elevara Medicines Limited
Phase 2
180
Arizona, California, Colorado, Florida, Louisiana, Michigan, North Carolina, Pennsylvania
2026-02-18
Recruiting
Crescent Biopharma, Inc.
Phase 1/2
540
Alabama, California, Colorado, District of Columbia, Florida, Michigan, New York, Ohio
2026-02-17
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Alabama, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-02-16
Recruiting
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
80
California, Colorado, Florida, Kansas, Massachusetts, Michigan, Minnesota, New York
2026-02-10
Active, closed
Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.
Phase 2
8
Arizona, California, Colorado, Florida, Georgia, Illinois, North Carolina, North Dakota
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Alabama, California, Colorado, Florida, Georgia, Louisiana, Maryland, Michigan
2026-02-10
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2026-02-08
Recruiting
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-05
Recruiting
Eli Lilly and Company
Phase 3
300
Colorado, Florida, Pennsylvania, Texas, Virginia
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Colorado, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina, Tennessee
2026-02-03
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Active, closed
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Prilenia
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland
2026-02-01
Recruiting
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
NCT07422675PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
Serina Therapeutics
Phase 1
40
Colorado, Florida, Michigan, Washington
2026-02-01
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Pfizer
Phase 1/2
162
Arkansas, California, Colorado, Florida, Massachusetts, New Jersey, New York, Oregon
2026-01-30
Recruiting
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-01-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
California, Colorado, Florida, Kentucky, Missouri, New Jersey, Oregon, South Dakota
2026-01-29
Recruiting
Dewpoint Therapeutics
Phase 1
60
California, Colorado, Connecticut, New York, Tennessee, Texas, Virginia
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
By invitation
Immunovant Sciences GmbH
Phase 2
372
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Indiana
2026-01-26
Recruiting
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
NCT07287917Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.
Phase 1/2
92
Arizona, California, Colorado, Kansas, Michigan, Minnesota, New York, Ohio
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Arizona, California, Colorado, Florida, Maryland, Massachusetts, Michigan, Minnesota
2026-01-25
Recruiting
Sanofi
Phase 3
751
Colorado, Florida, Illinois, Indiana, Louisiana, Missouri, New York, North Carolina
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
California, Colorado, Florida, Illinois, Louisiana, Massachusetts, Minnesota, Nebraska
2026-01-22
Recruiting
Regeneron Pharmaceuticals
Phase 1
54
Colorado, Massachusetts, Texas
2026-01-19
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-01-19
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)
Starlight Cardiovascular Inc
Not applicable
45
California, Colorado, Maryland, Massachusetts, Ohio, Pennsylvania, Texas, Washington
2026-01-16
Recruiting
Kahr Bio Australia Pty Ltd
Phase 2
90
Colorado, Florida, North Carolina, Pennsylvania, Texas
2026-01-16
Recruiting
Sanofi
Phase 3
751
Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-16
Recruiting
Axcynsis Therapeutics Pte Ltd
Phase 1
83
Colorado, Connecticut, Oregon, South Carolina
2026-01-14
Recruiting
Sanofi
Phase 3
160
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland
2026-01-14
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 3
80
California, Colorado, Nevada, Ohio, Texas, Utah
2026-01-14
Recruiting
Renibus Therapeutics, Inc.
Phase 3
150
California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana
2026-01-13
Recruiting
Ardelyx
Phase 3
692
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-01-13
Recruiting
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT07188558Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.
Phase 3
400
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2026-01-12
Recruiting
Enveda Therapeutics
Phase 2
50
Alabama, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2026-01-09
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
By invitation
Medtronic
Observational
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2026-01-07
Recruiting
Skyhawk Therapeutics, Inc.
Phase 2/3
400
Colorado, Massachusetts, Ohio
2026-01-06
Recruiting
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
GRIN Therapeutics, Inc.
Phase 3
100
California, Colorado, District of Columbia, Florida, Iowa, Massachusetts, New Jersey, New York
2026-01-05
Recruiting
Biogen
Phase 2
81
California, Colorado, Illinois, Kansas, Michigan, Minnesota, Missouri, Nebraska
2026-01-05
Recruiting
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587Advanced Pheochromocytoma and Paraganglioma, PCPG
DrugONC206
Jazz Pharmaceuticals
Phase 2
90
California, Colorado, Michigan, Minnesota, Missouri, New York, Pennsylvania, Utah
2026-01-02
Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
NCT07335601MASH - Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals, Inc.
Phase 2
120
California, Colorado, District of Columbia, Illinois, Minnesota, Nebraska, New York, Tennessee
2025-12-29
Recruiting
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
Active, closed
Organon and Co
Phase 3
187
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-12-29
Recruiting
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-22
Recruiting
Mahzi Therapeutics
Phase 1/2
12
California, Colorado, Illinois
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Kansas
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Arizona, California, Colorado, Florida, Georgia, Maryland, Missouri, Nebraska
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
California, Colorado, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Missouri
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas
2025-12-17
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2025-12-16
Recruiting
N-Fold, LLC
Phase 1/2
68
Colorado
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Colorado, Florida, New Jersey, New York, Ohio, Washington
2025-12-16
Active, closed
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
NCT07220811Immune System Diseases, Ig-E Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Phase 2
110
Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Massachusetts
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2025-12-15
Recruiting
AstraZeneca
Phase 2
320
Arizona, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
Ascendis Pharma A/S
Phase 3
186
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Idaho
2025-12-12
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.
Phase 3
150
California, Colorado, Florida, Georgia, Illinois, Maryland, Michigan, Minnesota
2025-12-11
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-11
Recruiting
TuHURA Biosciences, Inc.
Phase 2/3
118
California, Colorado, Florida, Massachusetts, Minnesota, New Jersey, North Carolina, Pennsylvania
2025-12-11
Recruiting
Protara Therapeutics
Phase 2/3
129
Colorado, Florida, Illinois, Nebraska, New York, North Carolina, Ohio, Texas
2025-12-10
Recruiting
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Michigan, Minnesota
2025-12-10
Recruiting
GT Medical Technologies, Inc.
Phase 3
766
Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-10
Active, closed
Incyte Corporation
Phase 3
13
Alaska, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2025-12-09
Recruiting
AstraZeneca
Phase 1
24
Arizona, Colorado, District of Columbia, Illinois, Missouri, New York, Ohio, Washington
2025-12-09
Recruiting
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07216443Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
DrugOrca-T
Orca Biosystems, Inc.
Phase 2
130
California, Colorado, Florida, Minnesota, New Jersey, New York, Oregon, Tennessee
2025-12-09
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
Satellos Bioscience, Inc.
Phase 2
51
California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington
2025-12-08
Recruiting
Mabylon AG
Phase 1
56
Arkansas, Colorado, Florida, Massachusetts, Michigan, Texas
2025-12-06
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
Generate Biomedicines
Phase 3
786
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-12-03
Recruiting
Akebia Therapeutics
Phase 2
60
California, Colorado, Florida, Georgia, Illinois, Kentucky, Maryland, Massachusetts
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Indiana
2025-12-03
Recruiting
Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization
NCT07224906Pulmonary Hypertension, Congestive Heart Failure(CHF), Valve Disease, Heart
HemoCept Inc.
Observational
50
Colorado
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
Sun Pharmaceutical Industries, Inc.
Phase 3
260
Arizona, California, Colorado, Florida, Idaho, Illinois, Indiana, Maryland
2025-11-29
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
California, Colorado, Florida, Georgia, Illinois, Indiana, Mississippi, New York
2025-11-28
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Novartis Pharmaceuticals
Phase 3
31
California, Colorado, Florida, Pennsylvania, Utah
2025-11-27
By invitation
Soleno Therapeutics, Inc.
Observational
200
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-11-26
Active, closed
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
Active, closed
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2025-11-25
Recruiting
Regeneron Pharmaceuticals
Phase 3
2,000
California, Colorado, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts
2025-11-24
Recruiting
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
NCT07403188Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA)
Kyverna Therapeutics
Observational
70
Colorado
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts
2025-11-22
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Recruiting
Neurotech Pharmaceuticals
Phase 4
234
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-11-21
Recruiting
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
NCT07136181Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
Novelwise Pharmaceutical Corporation
Phase 1/2
36
Arizona, Colorado, Tennessee
2025-11-20
Recruiting
Bayer
Phase 3
111
Colorado, Delaware, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2025-11-19
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Arizona, California, Colorado, Florida, Minnesota, Ohio, Pennsylvania, Texas
2025-11-18
Recruiting
BioNTech SE
Phase 1/2
245
Colorado, Florida, Michigan, New York
2025-11-18
Recruiting
Summit Therapeutics
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2025-11-18
Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432HER2 Expressing Solid Tumors
Vironexis Biotherapeutics Inc.
Phase 1/2
27
California, Colorado, Florida, Minnesota, New Jersey, New York, Ohio, Pennsylvania
2025-11-18
Recruiting
Sanofi
Observational
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Michigan
2025-11-17
Recruiting
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
NCT07284667Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACADIA Pharmaceuticals Inc.
Phase 2
153
Alabama, California, Colorado, Florida, Massachusetts, Mississippi, Missouri, Nebraska
2025-11-14
Active, closed
Hoffmann-La Roche
Phase 2
193
California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington
2025-11-13
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Allogene Therapeutics
Phase 1
66
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Kentucky
2025-11-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
Eli Lilly and Company
Phase 2
252
Arizona, California, Colorado, Florida, Illinois, Indiana, Kentucky, Massachusetts
2025-11-10
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Colorado, Iowa, Massachusetts, New York, North Carolina, Tennessee
2025-11-10
Recruiting
Regeneron Pharmaceuticals
Phase 3
20
Arizona, California, Colorado, Georgia, Massachusetts, New York, North Carolina, Pennsylvania
2025-11-10
Recruiting
Avisi Technologies Inc.
Not applicable
165
Arizona, California, Colorado, New York, Pennsylvania, Texas, Wisconsin
2025-11-07
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Active, closed
Saol Therapeutics Inc
Phase 3
150
California, Colorado, District of Columbia, Florida, Minnesota, North Carolina, Oklahoma, Oregon
2025-11-07
Recruiting
Managing Pain Using Optimized Sequences by Adjusting Parameters With Independent Current Control
NCT07190807Chronic Pain, Intractable Pain, Low Back Pain, Chronic Low-back Pain
Boston Scientific Corporation
Not applicable
70
Colorado, Florida, Louisiana, New York, Pennsylvania, South Carolina, Texas
2025-11-07
Recruiting
AstraZeneca
Phase 2
435
California, Colorado, District of Columbia, Florida, Georgia, Kansas, Michigan, Minnesota
2025-11-06
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Colorado, Florida, Illinois, Massachusetts, Missouri, New Jersey, New York, Ohio
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
California, Colorado, Florida, Georgia, Illinois, Massachusetts, Missouri, Nevada
2025-11-05
Recruiting
AbbVie
Phase 3
561
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2025-11-05
Recruiting
Exploring the Extended Efficacy and Initial Use of RUCONEST® in Managing Neurological Symptoms Linked to Infectious Pathogens
NCT07932002Post SARS-CoV2 (COVID-19), Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), COVID - 19
IMMUNOe Research Centers
Phase 4
30
Colorado
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-11-04
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Oncology, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Active, closed
CastleVax Inc.
Phase 2
200
Colorado, Massachusetts
2025-11-03
Active, closed
SecondWave Systems Inc.
Not applicable
60
Arizona, California, Colorado, Minnesota
2025-11-03
Recruiting
Incyte Corporation
Phase 1
24
Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky, Louisiana
2025-11-03
Recruiting
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
NCT06699121Primary Sclerosing Cholangitis (PSC)
LISCure Biosciences
Phase 2
87
California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington
2025-11
Recruiting
Eli Lilly and Company
Phase 3
1,205
Alabama, Arizona, California, Colorado, Florida, Indiana, Maryland, Michigan
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Arizona, California, Colorado, Delaware, District of Columbia, Florida, Georgia, Illinois
2025-10-31
Recruiting
Pfizer
Phase 2
200
Arizona, Arkansas, California, Colorado, Illinois, Maryland, Michigan, New York
2025-10-30
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Active, closed
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Candel Therapeutics, Inc.
Phase 2
45
Arizona, Colorado, Maryland, Nevada, New Jersey, South Carolina
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
Alabama, Arizona, California, Colorado, Florida, Indiana, Louisiana, Maryland
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
NCT06701656Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome
PPD Development, LP
Phase 2
200
Alabama, California, Colorado, District of Columbia, Florida, Idaho, Illinois, Massachusetts
2025-10-28
Recruiting
GlaxoSmithKline
Phase 3
1,200
Arizona, Arkansas, California, Colorado, Florida, Georgia, Kansas, Louisiana
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 1
30
Colorado, Indiana, Iowa, Pennsylvania
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Eli Lilly and Company
Phase 2
531
Arizona, California, Colorado, Florida, Illinois, Kentucky, Massachusetts, Nevada
2025-10-22
Recruiting
Biosense Webster, Inc.
Not applicable
276
Arizona, California, Colorado, Florida, Illinois, Iowa, Kansas, Michigan
2025-10-21
Recruiting
GlaxoSmithKline
Phase 1/2
47
Colorado, Michigan, Ohio, Tennessee
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-10-20
Recruiting
ONWARD Medical, Inc.
Not applicable
60
Arkansas, Colorado, Florida, Georgia, Kentucky, Maryland, Massachusetts, Minnesota
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
Nurix Therapeutics, Inc.
Phase 2
100
Arizona, California, Colorado, Florida, Illinois, Indiana, Iowa, Maryland
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Colorado, Florida, Illinois, Maryland
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington
2025-10-15
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
NCT07174583Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
IDEAYA Biosciences
Phase 1/2
262
Colorado, Florida, Indiana, Michigan, New York, Pennsylvania, Tennessee, Texas
2025-10-14
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Arizona, California, Colorado, Florida, Illinois, Michigan, Missouri, Nebraska
2025-10-08
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
A Study of CTD402 in T-ALL/LBL Patients
NCT07070219Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
Imviva Bio
Phase 1/2
118
California, Colorado, Illinois, Minnesota, New York, Tennessee, Texas
2025-10-07
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
Incyte Corporation
Phase 1
120
Arizona, California, Colorado, Florida, Illinois, Maryland, New York, North Carolina
2025-10-01
Recruiting
AllRock Bio, Inc.
Phase 2
40
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Michigan, Ohio
2025-10-01
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
By invitation
Astria Therapeutics, Inc.
Phase 3
145
Arizona, Arkansas, California, Colorado, Maryland, Ohio, Pennsylvania
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2025-09-30
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Maryland, Massachusetts
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, Pennsylvania
2025-09-30
Recruiting
Pfizer
Phase 3
680
Alabama, Alaska, Arkansas, California, Colorado, Delaware, Florida, Georgia
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
California, Colorado, Florida, Illinois, New York, North Carolina, Utah
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois
2025-09-28
Active, closed
Merck Sharp & Dohme LLC
Phase 2
315
Arizona, California, Colorado, Florida, Illinois, Maryland, Missouri, Montana
2025-09-26
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2025-09-26
Recruiting
Daiichi Sankyo
Phase 2/3
630
California, Colorado, Florida, Georgia, Illinois, Maryland, Massachusetts, Michigan
2025-09-26
Active, closed
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Legacy Medical Consultants
Observational
2,400
Colorado, Michigan, Oklahoma, West Virginia
2025-09-25
Recruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
Jazz Pharmaceuticals
Phase 2
125
California, Colorado, Florida, Illinois, Iowa, Louisiana, Maine, Maryland
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
Rhythm Pharmaceuticals, Inc.
Phase 3
39
Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington
2025-09-23
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Astellas Pharma Global Development, Inc.
Phase 1
40
California, Colorado, Georgia, Illinois, Michigan, Missouri, New Jersey, Texas
2025-09-22
Active, closed
Vanda Pharmaceuticals
Phase 3
500
Arizona, California, Colorado, Florida, Georgia, Louisiana, Maryland, Missouri
2025-09-22
Recruiting
Study of Student Flourishing
NCT07259746Healthy
Flourish Science, Inc.
Not applicable
2,500
California, Colorado, Hawaii, Kansas, Rhode Island, Washington, Wisconsin
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-09-22
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
Sanofi
Phase 3
942
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Louisiana, Pennsylvania
2025-09-16
Recruiting
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
Scholar Rock, Inc.
Phase 2
52
Arizona, California, Colorado, Georgia, Iowa, Michigan, Pennsylvania, Texas
2025-09-15
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
414
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
Annexon, Inc.
Phase 3
30
Arizona, California, Colorado, District of Columbia, Florida, Kansas, Louisiana, Massachusetts
2025-09-12
Recruiting
A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO
NCT07205887Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.
Phase 2
160
Arizona, California, Colorado, Florida, Illinois, Maryland, Mississippi, New Jersey
2025-09-12
Recruiting
Pfizer
Phase 3
140
California, Colorado, District of Columbia, Florida, Illinois, Indiana, Maryland, Michigan
2025-09-10
Recruiting
Janssen Research & Development, LLC
Phase 3
220
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Louisiana
2025-09-10
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-06
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Arizona, Arkansas, California, Colorado, Florida, Maryland, Michigan, Missouri
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Arizona, California, Colorado, Florida, Illinois, Kansas, Maine, Missouri
2025-08-27
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
Tasca Therapeutics
Phase 1/2
150
Colorado, Florida, Michigan, Missouri, Nebraska, North Carolina, Ohio, Pennsylvania
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
Climb Bio, Inc.
Phase 2
45
Colorado, Florida, Georgia, Indiana, New York, Texas
2025-08-25
Recruiting
Pfizer
Phase 3
6,000
Alabama, Arizona, California, Colorado, Florida, Idaho, Louisiana, Maryland
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx
Phase 3
218
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Kentucky, Louisiana
2025-08-22
Recruiting
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Recruiting
Boston Scientific Corporation
Not applicable
1,616
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Massachusetts
2025-08-21
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
MapLight Therapeutics
Phase 2
300
Arizona, California, Colorado, Florida, Georgia, Louisiana, Nevada, New Jersey
2025-08-15
Recruiting
Takeda
Phase 3
150
Arkansas, California, Colorado, District of Columbia, Georgia, Indiana, Iowa, Kentucky
2025-08-14
Recruiting
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922Epileptic Encephalopathy, SCN2A Encephalopathy
Praxis Precision Medicines
Phase 3
40
California, Colorado, Illinois, Ohio, Pennsylvania, Tennessee
2025-08-13
Recruiting
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Active, closed
Novo Nordisk A/S
Phase 3
877
Alabama, California, Colorado, Florida, Georgia, Idaho, Illinois, Indiana
2025-08-11
Rows per page Showing 1–500 of 2073
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/colorado

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,073 of those studies with a site in Colorado.

How many clinical trials are recruiting in Colorado?

1,031 of the 2,073 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 25 have not yet opened recruitment, 949 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Colorado), 2,073 studies
PhaseStudiesRecruitingShare
Phase 381937039.5%
Phase 235417217.1%
Not applicable2108310.1%
Phase 11991249.6%
Phase 1/21981269.6%
Observational183968.8%
Phase 2/376443.7%
Phase 433161.6%
Early Phase 1100%

Most active sponsors

Lead sponsors with the most studies (Colorado)
Lead sponsorStudiesRecruiting
AstraZeneca8842
Janssen Research & Development, LLC7132
Eli Lilly and Company6632
Merck Sharp & Dohme LLC6638
Novartis Pharmaceuticals5624
AbbVie5323
Hoffmann-La Roche5318
Pfizer4830
Bristol-Myers Squibb3421
Sanofi2913
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.